Clearmind Medicine develops novel psychedelic medicines to solve widespread, yet under-served, health problems. Clearmind’s flagship treatments are focused on alcohol abuse and binge drinking.
Stock Performance
Clearmind News 127 articles
- Clearmind Medicine granted U.S. patent for binge behavior regulators
- Clearmind reaches 20 patients dosed in CMND-100 alcohol use disorder trial
- SciSparc unit NeuroThera and Clearmind file Hong Kong patent for combination depression therapy
- Clearmind publishes international patent covering weight-loss and fatty-liver therapy
- Clearmind's CMND-100 alcohol-use-disorder trial advances after DSMB clearance
- Clearmind reports additional positive safety data for CMND-100 in alcohol use disorder
- Clearmind initiates leading Israeli site for CMND-100 alcohol-use-disorder trial
- Clearmind adds Johns Hopkins site to Phase I/IIa alcohol-use-disorder trial of CMND-100
- SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
- SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
- Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
- Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
- Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
- Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
- Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
- Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
- Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
- Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
- Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
- Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
- Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
- Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
- Clearmind Medicine Announces Shareholders Meeting Results
- SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
- Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
- Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
- Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
- Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
- Clearmind Medicine : FDA approval for the IND submission to conduct its trial already secured Form 6K
- Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
- Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
- Clearmind Medicine: New Scientific Publication Shows MEAI’s Potential as a Novel Weight Loss Drug
- SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
- Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
- Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
Showing the 40 most recent of 127 articles.